Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4442319 | 0.99 | IDO1 (0.36) | IDO1HTT | |
| Hydrochloric Acid SCHEMBL4442352 | 0.99 | IDO1 (0.36) | IDO1HTT | |
| SCHEMBL3686322 | 0.84 | IDO1 (0.34) | IDO1 | |
| SCHEMBL3687314 | 0.84 | IDO1 (0.46) | IDO1MAPTHTT | |
| Hydrochloric Acid SCHEMBL4446717 | 0.83 | IDO1 (0.35) | IDO1 | |
| Hydrochloric Acid SCHEMBL4442317 | 0.83 | IDO1 (0.48) | IDO1MAPTHTT | |
| Hydrochloric Acid SCHEMBL4442348 | 0.83 | IDO1 (0.48) | IDO1MAPTHTT | |
| SCHEMBL3688893 | 0.82 | IDO1 (0.41) | IDO1MAPTHTT | |
| Bromide SCHEMBL4448371 | 0.81 | IDO1 (0.40) | IDO1MAPTHTT | |
| SCHEMBL3688652 | 0.81 | PTGS2 (0.33) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010005851-A1 | COMBINATION THERAPY FOR TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-01-14 | — | — | WO | claimed |
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | claimed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | claimed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | claimed |
| WO-2010005851-A1 | COMBINATION THERAPY FOR TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-01-14 | — | — | WO | disclosed |
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | FECH, SLC10A1, SLC40A1 | IDO1 269/4885MAPT 661/4885HTT 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.